Access Vascular and Medline Partner on Commercialization of Cobranded Vascular Access Catheters

June 23, 2026—Access Vascular, Inc. (AVI) and Medline announced a multiyear agreement to accelerate the rollout of AVI’s next-generation catheters, the HydroMid and HydroPICC.

According to the press release, the initiative bolsters Medline’s existing portfolio in vascular access while leveraging its acute care market presence and clinical expertise in infection prevention and ability to deliver customized kitting solutions.

The HydroMid and HydroPICC catheters, which received an antithrombogenic indication from the FDA in October 2025, feature AVI’s hydrogel material with antithrombogenic properties to help address catheter-related complications such as thrombosis and occlusion, noted the companies.

The companies stated that cobranded, codeveloped products are expected to be available through Medline starting in late 2026. They will be integrated into fully assembled, customizable procedure kits delivered to health systems nationwide, including the Prime Vendor customers in which Medline is the primary medical-surgical product supplier.

By combining AVI’s biomaterial technology—designed to reduce complications and improve patient outcomes—with Medline’s kitting and supply chain capabilities, the agreement is intended to deliver a streamlined, procedure-ready solution to help improve efficiency, support consistency in care, and strengthen supply resiliency, noted the press release.

Matthew Ostroff, RN, Vascular Access Coordinator at St. Josephs Health in Paterson, New Jersey, commented on the initiative in the companies’ press release.

“Reducing infection risk and improving catheter performance in vascular access has been a priority in our practice for years,” stated Ostroff. “Innovations that address those challenges—particularly without relying on chemical additives—are worth paying attention to.”

He continued, “Solutions that can be scaled through broad distribution networks have the potential to set a new standard for performance and patient care, and that matters at the bedside every day. Collaborations like this have the potential to drive meaningful progress, giving clinicians the tools to reduce complications, improve efficiency, and consistently elevate the quality of care they deliver. That’s the kind of advancement our field needs.”